Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eradication of minimal residual disease in hairy cell leukemia.
Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Ravandi F, et al. Blood. 2006 Jun 15;107(12):4658-62. doi: 10.1182/blood-2005-11-4590. Epub 2006 Feb 23. Blood. 2006. PMID: 16497968 Free article. Clinical Trial.
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.
Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Wierda WG, et al. J Clin Oncol. 2011 Nov 1;29(31):4088-95. doi: 10.1200/JCO.2010.33.9002. Epub 2011 Oct 3. J Clin Oncol. 2011. PMID: 21969505 Free PMC article. Clinical Trial.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Faderl S, et al. Among authors: koller c. Blood. 2003 May 1;101(9):3413-5. doi: 10.1182/blood-2002-07-1952. Epub 2003 Jan 9. Blood. 2003. PMID: 12522009 Free article. Clinical Trial.
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Thomas DA, et al. Among authors: koller c. Blood. 2004 Sep 15;104(6):1624-30. doi: 10.1182/blood-2003-12-4428. Epub 2004 Jun 3. Blood. 2004. PMID: 15178574 Free article. Clinical Trial.
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Wierda W, et al. Among authors: koller c. J Clin Oncol. 2005 Jun 20;23(18):4070-8. doi: 10.1200/JCO.2005.12.516. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767647
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Keating MJ, et al. Among authors: koller c. J Clin Oncol. 2005 Jun 20;23(18):4079-88. doi: 10.1200/JCO.2005.12.051. Epub 2005 Mar 14. J Clin Oncol. 2005. PMID: 15767648 Clinical Trial.
321 results